Content of certain cytokines and chemokines in blood ofpatients with chronic hepatitis B in the early stages of liver fibrosis

Hepatitis B is an infectious viral disease in which damage or destruction of liver tissue occurs, and which can turn into a chronic form. In chronic hepatitis B (CHB), hepatocytes are replaced by connective tissue as they die, resulting in fibrosis, and then cirrhosis of the liver. Early diagnosis of liver fibrosis is an urgent task in the development of CHB. Already at this stage of the disease, the immune system is activated, which plays a leading role in liver damage in CHB. The main regulators of immune processes are cytokines, which mediate intercellular interactions. A separate group of cytokines are chemokines — proteins of cell migration. In CHB, they are responsible for infiltration of liver tissue by activated white blood cells. Cytokines and chemokines are active participants in fibrogenesis, so they can serve as biomarkers for the development of liver fibrosis, including in the early stages. The purpose of this study was to analyze the content of certain cytokines/chemokines in the peripheral blood of patients with CHB in order to search for potential biomarkers of the initial stages of liver fibrosis. The study included 30 patients with a confirmed diagnosis of CHB with stages of liver fibrosis F0-F1 on the Metavir scale, 36 patients with a diagnosis of chronic hepatitis C (F0-F1) and 37 conditionally healthy individuals as a control group. Concentrations of the following cytokines/chemokines were determined: IFNγ, TNFα, CCL2/MCP-1, CCL8/MCP-2, CCL20/MIP-3α, CXCL9/MIG, CXCL10/IP-10, CXCL11/I-TAC by multiplex analysis using xMAP technology (Luminex, USA). As a result of the study, it was found that in patients with CHB, the plasma content of cytokine TNFα and chemokines CCL2/MCP-1, CXCL9/MIG and CXCL10/IP-10 was increased, and the chemokine CCL8/MCP-2 was reduced, which indicates the possibility of using these cytokines/chemokines as biomarkers of liver damage in CHB. In the examined group of patients with CHB, there was no dependence of the concentrations of cytokines and chemokines in the blood plasma on the viral load, which may be explained by its low level. For plasma cytokines in patients with CHB, correlations were found between TNFα and CCL2/MCP-1 and CCL8/MCP-2 chemokines , which was not observed in the control group. At the same time, in the control group, a correlation was found between the content of TNFα and the chemokine CXCL9/MIG, which was not detected in the group of patients. For both groups, a correlation was found between the content of CXCL9/MIG and CXCL10/IP-10 chemokines. Based on the study data, an algorithm has been developed that allows us to establish chronic hepatitis B or chronic hepatitis C as the cause of the initial form of fibrosis F0-F1 in terms of the content of cytokines IFNγ, CCL2/MCP-1 and CCL8/MCP-2 in blood plasma with a diagnostic efficiency of 89.4%.

1. Arsentieva N.A., Semenov A.V., Zhebrun D.A., Vasilyeva E.V., Totolian Areg A. Role of CXCR3 chemokine receptor and its ligands in certain diseases. Meditsinskaya immunologiya = Medical Immunology (Russia), 2019, Vol. 21, no. 4, pp. 617-632. (In Russ.) doi: 10.15789/1563-0625-2019-4-617-632.

2. rsentyeva N.A., Semenov A.V., Lyubimov N.E., Basina V.V., Esaulenko E.V., Kozlov K.V., Zhdanov K.V., Totolyan Areg A. Contents cytokines and chemokines in blood plasma of patients with chronic viral hepatitis C. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2015, Vol. 9 (18), no. 1, pp. 83-92. (In Russ.)

3. Demidenko T.P., Neverov V.A. Viral hepatitis: a guide for doctors. Ed. Yu.V. Lobzin. St. Petersburg, 2011. 229 p.

4. Pokrovsky VI., Pak S.G., Briko N.I., Danilkin B.K. Infectious diseases and epidemiology: textbook. Moscow: GEOTAR-Media, 2012. 1008 p.

5. Surkov A.N., Namazova-Baranova L.S., Gevorkyan A.K. Non-invasive diagnosis of liver fibrosis and cirrhosis in chronic viral hepatitis. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics, 2016, Vol. 61, no. 4, pp. 209-214. (In Russ.)

6. Ярилин А.А. Иммунология: учебник. М.: ГЭОТАР-Медиа, 2010. 752 с. [Yarilin A.A. Immunology: textbook]. Moscow: GEOTAR-Media, 2010. 752 p.

7. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., Huang G.T., Iloeje U.H., REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, Vol. 295, no. 1, pp. 65-73.

8. Global Hepatitis Report 2017. Geneva: World Health Organization, 2017. Accessed August 14, 2019. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.

9. Lee A.Y.S., Korner H. The CCR6-CCL20 axis in humoral immunity and T-B cell immunobiology. Immunobiol., 2019, Vol. 224, no. 3, pp. 449-454.

10. Mah A.Y., Cooper M.A. Metabolic regulation of Natural Killer Cell IFN-y production. Crit. Rev. Immunol., 2016, Vol. 36, no. 2, pp. 131-147.

11. Metzemaekers M., Vanheule V, Janssens R., Struyf S., Proost P. Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Front. Immunol, 2018, Vol. 8, 1970. doi: 10.3389/fimmu.2017.01970.

12. van Raemdonck K., van den Steen P.E., Liekens S., van Damme J., Struyf S. CXCR3 ligands in disease and therapy. Cytok. Gro. Fact. Rev., 2015, Vol. 26, no. 3, pp. 311-327.

13. Yang X.W., Wang X.S., Cheng F.B., Wang F., Wan L., Wang F., Huang H.X. Elevated CCL2/MCP-1 levels are related to disease severity in postmenopausal osteoporotic patients. Clin. Lab., 2016, Vol. 62, no. 11, pp. 2173-2181.

14. Zhang J., Patel L., Pienta K.J. Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog. Mol. Biol. Transl. Sci., 2010, Vol. 95, pp. 31-53.